Hilltop National Bank Makes New $662,000 Investment in Sanofi $SNY

Key Points

• Hilltop National Bank invested approximately $662,000 in Sanofi, acquiring 13,705 shares during the second quarter, marking a significant new position for the bank.
• Sanofi's recent earnings report showed an EPS of $0.90, missing analysts' expectations, while the company generated $11.34 billion in revenue, exceeding estimates but down 7% year-over-year.
• Analysts are optimistic about Sanofi's stock, with two strong buy ratings and an average price target of $62.67, indicating potential for growth despite current challenges.

Hilltop National Bank bought a new position in Sanofi (NASDAQ:SNY - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,705 shares of the company's stock, valued at approximately $662,000.

Several other hedge funds have also modified their holdings of the stock. Cardinal Capital Management boosted its holdings in shares of Sanofi by 0.3% in the 1st quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock valued at $3,827,000 after purchasing an additional 199 shares during the last quarter. Perigon Wealth Management LLC boosted its holdings in Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock valued at $367,000 after acquiring an additional 201 shares during the last quarter. Capital Analysts LLC boosted its holdings in Sanofi by 14.0% in the first quarter. Capital Analysts LLC now owns 1,664 shares of the company's stock valued at $92,000 after acquiring an additional 204 shares during the last quarter. Thomasville National Bank boosted its holdings in Sanofi by 0.3% in the second quarter. Thomasville National Bank now owns 80,440 shares of the company's stock valued at $3,886,000 after acquiring an additional 211 shares during the last quarter. Finally, Beacon Financial Group lifted its stake in shares of Sanofi by 1.6% in the 1st quarter. Beacon Financial Group now owns 14,398 shares of the company's stock valued at $799,000 after purchasing an additional 222 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Up 1.5%

NASDAQ SNY opened at $50.90 on Friday. The company's fifty day simple moving average is $48.19 and its 200-day simple moving average is $50.09. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The stock has a market cap of $124.99 billion, a P/E ratio of 12.24, a PEG ratio of 1.19 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same quarter in the prior year, the firm earned $1.73 EPS. The business's quarterly revenue was down 7.0% compared to the same quarter last year. Equities research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the topic of several research analyst reports. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Sanofi in a research report on Saturday, September 27th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Tuesday, September 2nd. Barclays restated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of "Buy" and an average price target of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.